First in Human Study of TORL-1-23 in Participants With Advanced Cancer

Trial Details

NCT ID

NCT05103683

Phase

PHASE1

Sponsor

TORL Biotherapeutics, LLC

Status

RECRUITING

Cancer Type

Uterine Cancer

Interventions

• TORL-1-23

Locations (sample)

• Fullerton, California, United States|33.87029,-117.92534
• Los Angeles, California, United States|34.05223,-118.24368
• Lexington, Kentucky, United States|37.98869,-84.47772
• Minneapolis, Minnesota, United States|44.97997,-93.26384
• Rochester, Minnesota, United States|44.02163,-92.4699

Key Eligibility Criteria

• Advanced solid tumor
• Measurable disease, per RECIST v1.1
• Eastern Cooperative Oncology Group (ECOG) performance status 0-1
• Adequate organ function

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.